UNH
UNITEDHEALTH GROUP INC
UnitedHealth Group Inc has a market capitalization of $371.03B and a current price of $407.28, reflecting a decrease of 0.82% from the previous close of $410.63. The company's P/E ratio stands at 30.78, while its P/S ratio is 0.83, indicating a revenue growth of 11.81% year-over-year despite an EPS growth decline of 14.70%. The company's dividend yield is 2.13%, and the stock has fluctuated between a 52-week high of $461 and a low of $256.
The performance metrics indicate a mixed outlook for UnitedHealth Group, underscoring the importance of individual assessment before making investment decisions.
Johnson & Johnson has a market cap of $658.93B and a current stock price of $271.23, reflecting a 0.93% increase from the previous close of $268.73. The company shows a P/E ratio of 24.59 and an impressive EPS growth of 90.50% year-over-year. Revenue growth stands at 6.05% year-over-year, while the 52-week range has been between $185 and $281.01.
Investors should consider the mixed signals regarding valuation and growth potential when evaluating Johnson & Johnson.
Key metrics
THE NUMBERS, SIDE BY SIDEFinancial metrics for UNH and JNJ| Metric | UNH | JNJ |
|---|
| Price | $407.27 | $271.23 |
|---|
| Market Cap | $371.03B | $658.93B |
|---|
| P/E Ratio | 30.78 | 24.59 |
|---|
| EPS Growth (YoY) | -14.7% | 90.5% |
|---|
| Revenue Growth (YoY) | 11.81% | 6.05% |
|---|
| ROE | 12.05% | 32.87% |
|---|
| Gross Margin | N/A | 67.88% |
|---|
| Net Margin | 2.69% | 28.46% |
|---|
| 52W High | $461.00 | $281.01 |
|---|
| 52W Low | $256.00 | $185.00 |
|---|
| Dividend Yield | 2.13% | N/A |
|---|
| Beta | N/A | N/A |
|---|
| D/E Ratio | 0.72 | 0.48 |
|---|
| Current Ratio | 0.79 | 1.03 |
|---|
Bull & bear cases
WEIGH BOTH SIDESUNH
Bull Case
Some investors cite UnitedHealth Group's revenue growth of 11.81% year-over-year as a strong indicator of its market position in the healthcare sector. Additionally, its dividend yield of 2.13% may appeal to income-focused investors during periods of market volatility.
Bear Case
Conversely, the company faces challenges with an EPS growth decline of 14.70%, which may raise concerns about profitability moving forward. Furthermore, the current ratio of 0.79 suggests potential liquidity issues compared to industry standards.
JNJ
Bull Case
Some investors highlight Johnson & Johnson's robust EPS growth of 90.50% year-over-year, suggesting strong profitability. Additionally, the company's recent positive trial data for cancer treatments indicates potential for future revenue streams.
Bear Case
Conversely, concerns arise from the stock's P/E ratio of 24.59, which some may view as high relative to industry peers. Furthermore, despite the positive growth metrics, the stock trades at a discount following a 97% run, implying potential overvaluation risks.
Frequently Asked Questions
How do UNH and JNJ compare?
UNITEDHEALTH GROUP INC: UnitedHealth Group Inc has a market capitalization of $371.03B and a current price of $407.28, reflecting a decrease of 0.82% from the previous close of $410.63. The company's P/E ratio stands at 30.78, while its P/S ratio is 0.83, indicating a revenue growth of 11.81% year-over-year despite an EPS growth decline of 14.70%. The company's dividend yield is 2.13%, and the stock has fluctuated between a 52-week high of $461 and a low of $256. Johnson & Johnson: Johnson & Johnson has a market cap of $658.93B and a current stock price of $271.23, reflecting a 0.93% increase from the previous close of $268.73. The company shows a P/E ratio of 24.59 and an impressive EPS growth of 90.50% year-over-year. Revenue growth stands at 6.05% year-over-year, while the 52-week range has been between $185 and $281.01.
Which has better growth potential, UNH or JNJ?
UNITEDHEALTH GROUP INC: Some investors cite UnitedHealth Group's revenue growth of 11.81% year-over-year as a strong indicator of its market position in the healthcare sector. Additionally, its dividend yield of 2.13% may appeal to income-focused investors during periods of market volatility. Johnson & Johnson: Some investors highlight Johnson & Johnson's robust EPS growth of 90.50% year-over-year, suggesting strong profitability. Additionally, the company's recent positive trial data for cancer treatments indicates potential for future revenue streams.
What are the risks of investing in UNH or JNJ?
UNITEDHEALTH GROUP INC risks: Conversely, the company faces challenges with an EPS growth decline of 14.70%, which may raise concerns about profitability moving forward. Furthermore, the current ratio of 0.79 suggests potential liquidity issues compared to industry standards. Johnson & Johnson risks: Conversely, concerns arise from the stock's P/E ratio of 24.59, which some may view as high relative to industry peers. Furthermore, despite the positive growth metrics, the stock trades at a discount following a 97% run, implying potential overvaluation risks.
RESEARCH IS JUST THE BEGINNING
Put the comparison in context.
Bring your holdings into Helm for portfolio intelligence, daily briefs, and thesis monitoring. Start with one position.
Not financial advice. Informational use only. AI-generated content may contain errors. Consult a licensed financial advisor before making investment decisions.